drugset / Trial / NCT06611423
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
Phase 1
Terminated
10 enrolled
AstraZeneca
CTC Clinical Trial Consultants AB · collabKarolinska Institutet · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).
Timeline
- Start
- 2024-10-15
- Primary completion
- 2025-08-21
- Completion
- 2025-08-21
Outcome
Outcome not reported
Stopped (Enrollment): “The Sponsor encountered difficulties in recruiting patients for clinical trial D8330C00004 and decided to end the study earlier for business reasons not affecting the benefit-risk balance.”